DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for granular corneal dystrophy type I — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGranular corneal dystrophy type I maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for granular corneal dystrophy type i is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transforming growth factor beta induced (TGFBI) — TGFBI is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5NV6 · 2.93 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Three eyes from two patients with recurrent granular dystrophy after corneal grafting were treated with excimer phototherapeutic keratectomy (PTK). Visual acuity improved in all three eyes and repeat corneal grafting was avoided. One eye had a further recurrence of granular deposits that was successfully retreated with excimer PTK. Follow-up ranged from five months to three years. The authors considered excimer PTK a simple, safe and repeatable way to restore visual acuity in most cases of recurrent granular dystrophy, avoiding the problems of repeat grafting.
In two Indian families with severe granular corneal dystrophy, mutation analysis of exon 12 of the TGFBI gene found a C to T mutation at residue 1710, corresponding to an Arg555Trp mutation in keratoepithelin. Five affected individuals were homozygous for this mutation and four were heterozygous. Homozygous individuals had a severe form of granular corneal dystrophy with early onset and superficial lesions; heterozygous individuals had a milder phenotype. Histopathology of corneal specimens from two homozygous patients confirmed superficial granular deposits. The authors noted that homozygous granular corneal dystrophy has a severe phenotype and can be recognised clinically, especially in association with consanguinity or inbreeding.
Granular corneal dystrophy is described as the commonest of the corneal dystrophies, usually causing visual disability in the fourth or fifth decades. Two unusual variations are juvenile granular dystrophy and Avellino dystrophy, which combines features of granular and lattice dystrophies.
No drug treatment is mentioned in any of these abstracts. What is missing is any controlled trial of a pharmacological intervention, any attempt to target the TGFBI gene product or the deposition process, and any patient stratification beyond the genotype-phenotype correlation described in two families. Funding for drug-repurposing screens in this rare disease, and a trial design that can measure corneal opacity change over years rather than months, remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Australian and New Zealand Journal of Ophthalmology · 1996 · 24 citations
Excirner phototherapeutic keratectomy for recurrent granular dystrophy
AbstractPURPOSE: Corneal grafting is a standard treatment for visually disabling granular dystrophy. The visual results of this procedure are generally good, but can be marred by recurrences of granular deposits some years later. We report the results of phototherapeutic keratectomy (PTK) for recurrent granular dystrophy in three eyes from two patients and discuss the possibilities of treating de novo granular dystrophy with excimer laser. METHODS: The records of two patients (three eyes) treated with excimer PTK for recurrent granular deposits on the donor cornea were reviewed. RESULTS: In all cases visual acuity was improved and repeat corneal grafting avoided. No significant complications occurred although one eye had further recurrence of granular deposits which was also successfully retreated with excimer PTK. Follow-up on these cases varies between five months and three years. CONCLUSIONS: We believe that excimer PTK offers a simple, safe and repeatable way of restoring visual acuity to most cases of recurrent granular dystrophy. Visual recovery is fast and all the incumbent problems of repeat grafting are avoided.
Archives of Ophthalmology · 2005 · 16 citations · open access
Genotype-Phenotype Correlation in 2 Indian Families With Severe Granular Corneal Dystrophy
AbstractOBJECTIVES: To determine genotypes in 2 Indian families with severe granular corneal dystrophy, to document clinical and histopathologic features, and to attempt a genotype-phenotype correlation. METHODS: Mutation analysis of exon 12 of the TGFBI gene was carried out in 9 individuals from 2 families. RESULTS: A C-->T mutation at residue 1710 of TGFBI complementary DNA, corresponding to an Arg555Trp mutation in keratoepithelin, was found in affected members of both families. In 5 patients, this mutation was homozygous, and it was heterozygous in the other 4. Clinical examination revealed a severe form of granular corneal dystrophy with early onset and superficial lesions in the homozygous individuals and a milder phenotype in the heterozygous individuals. Histopathologic evaluation of corneal specimens from 2 homozygous patients confirmed the presence of superficial granular deposits. CONCLUSIONS: To our knowledge, this is the first molecular and clinical characterization of severe granular corneal dystrophy in India. Genotype-phenotype correlation and comparison with earlier reports on this entity highlight the uniform expressivity of the Arg555Trp allele in homozygous individuals. CLINICAL RELEVANCE: Homozygous granular corneal dystrophy has a severe phenotype and can be recognized based on clinical and histopathologic features, especially in association with consanguinity or inbreeding.
Clinical and Experimental Optometry · 1999 · 3 citations
Granular dystrophy of the cornea
AbstractBACKGROUND: Granular corneal dystrophy is the commonest of the dystrophies and usually results in visual disability in the fourth or fifth decades. CASE HISTORY: A patient with granular corneal dystrophy is reported and the clinical characteristics described. DISCUSSION: The classical clinical features and the pathology and management of granular dystrophy are reviewed. Two unusual variations of the corneal dystrophy, namely, juvenile granular dystrophy and Avellino dystrophy, which is a concurrence of the features of granular and lattice dystrophies, are also described.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
